Tokai Pharmaceuticals Doses First Patient in a Phase 2 Study of Galeterone in Advanced Prostate Cancer
Published: Dec 13, 2012
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Tokai Pharmaceuticals, Inc., a biopharmaceutical company focused on developing new treatments for prostate cancer, today announced the treatment of the first patient in the ARMOR2 trial, a Phase 2 clinical study of its lead candidate galeterone (TOK-001) in patients with castration-resistant prostate cancer (CRPC). ARMOR2 is the second study in Tokai’s ARMOR (Androgen Receptor Modulation Optimized for Response) clinical development program for the evaluation of galeterone. Dosing occurred at the Urology Cancer Center and GU Research Network in Omaha, Neb. under the direction of Luke Nordquist, M.D., F.A.C.P.